Clinical trial NCT02012959: Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
Official title: A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA ® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Hyponatremia
Keywords: Hyponatremia
Euvolemic
Hypervolemic
Serum sodium
Dilutional hyponatremia
Electrolyte abnormality
Electrolyte imbalance
Metabolic disease
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
First posted: 2013-12-17
Enrollment: 9
Sex: ALL
Minimum age (years): 4
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial was to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent participants with euvolemic or hypervolemic hyponatremia.


Eligibility criteria: Inclusion:

* Male and female participants ≥4 weeks (or ≥44 weeks adjusted gestational age) to \<18 years old
* Participants hospitalized with euvolemic or hypervolemic hyponatremia resistant to initial standard background therapy
* Persistent euvolemic or hypervolemic hyponatremia defined as being documented as \<130 milliequivalent (mEq)/L and present for at least 48 hours, evidenced by at least 2 serum sodium assessments (12 hours apart)
* Ability to maintain adequate fluid intake (orally or intravenously)
* Ability to take oral medications
* Ability to comply with all requirements of the trial
* Completion of the trial-specific informed consent/assent as age appropriate
* Ability to commit to remain fully abstinent or practice double-barrier birth control as required by the trial

Exclusion:

* Evidence of hypovolemia or intravascular volume depletion
* Serum sodium \<120 mEq/L
* Use of potent cytochrome P450 3A4 (CYP3A4) inhibitors in participants \<12 kilogram (kg) or moderate CYP3A4 inhibitors in participants \<6 kg
* Lacks free access to water (inability to respond to thirst) or without intensive care unit level fluid monitoring and management
* History or current diagnosis of nephrotic syndrome
* Transient hyponatremia likely to resolve
* Hyperkalemia
* Estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared
* Acute kidney injury
* Severe or acute neurological symptoms requiring other intervention
* Prior treatment for hyponatremia with hypertonic saline within 8 hours of qualifying serum sodium assessments; urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of qualifying serum sodium assessments; any other treatments for the purpose of increasing serum sodium concurrent with dosing of trial medication
* Anuria or urinary outflow obstruction, unless participant is/can be catheterized
* History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives
* Psychogenic polydipsia
* Uncontrolled diabetes mellitus (defined as fasting glucose \>300 milligrams/deciliter)
* Screening liver function values \>3 times the upper limit of normal
* Participants who have cirrhosis and meet any of the following conditions: a major GI bleed within the past 6 months, evidence of active bleeding, platelet count \<50,000/microliter, or use of concomitant medications known to increase bleeding risk
* Hyponatremia due to the result of any medication that can safely be withdrawn or that is most appropriately corrected by alternative therapies
* History of drug or medication abuse within 3 months prior to screening or current alcohol abuse
* Participants who require suspension formulation and have a Hereditary Fructose Intolerance
* Has hyponatremia that is more appropriately corrected by alternative therapies
* Is pregnant or currently breastfeeding
* Has any medical condition that could interfere with evaluation of trial objectives or participant safety
* Has participated in another investigational drug trial in the last 30 days
* Weighs \<3 kg
* Unable to swallow tablets, if suspension unavailable
* Is deemed unsuitable for trial participation in the opinion of the investigator

Primary outcomes:
measure: Change In Serum Sodium Concentration For Responders
timeFrame: Day 2/2a, Day 4
Secondary outcomes:
measure: Change In Serum Sodium Concentration During Treatment Phase A
timeFrame: Baseline, Day 2/2a
measure: Fluid Balance (Intake Minus Output) During Treatment Phase A
timeFrame: Every 6 hours on Days 1 and 2
Other outcomes:
Locations:
city: Aurora
country: United States
state: Colorado
city: Washington
country: United States
state: District of Columbia
city: New York
country: United States
state: New York
city: Richmond
country: United States
state: Virginia
city: Seattle
country: United States
state: Washington
city: Rome
country: Italy
city: London
country: United Kingdom
Study officials:
affiliation: Otsuka Pharmaceutical Development & Commercialization, Inc.
name: Global Clinical Development
role: STUDY_DIRECTOR
References: